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The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated from fasting plasma glucose 3 and insulin levels using the following formula: HOMA-IR = fasting plasma glucose (mg/dL) × fasting plasma 4 insulin (µU/mL)/405.
6
Intraperitoneal insulin tolerance test 7 For the intraperitoneal insulin tolerance test (IPITT), mice were fasted for 5 h and injected intraperitoneally with 8 human insulin (1 U/kg body weight). Blood samples were collected from the tail vein at different time points. The 9 area under the curve (AUC) was calculated using the trapezoidal rule. forward primer 5'-CTGGTTGATCCTGCCAGTAG-3' and reverse primer 5'-CGACCAAAGGAACCATAACT-3'.
12
As an internal standard, 18S rRNA was chosen.
14

Western blot analysis
15
Adipose and liver tissues were prepared using a lysis buffer (20 mM Tris-HCl (pH 7.4), 1% NP40, 5 mM EDTA, 2 16 mM Na 3 VO 4 , 100 mM NaF, 10 mM Na 4 P 2 O 7 , 100 µM PMSF, 7 µg/mL aprotinin, and 7 µg/mL leupeptin Adipose tissue slides were prepared as described above and were stained with hematoxylin and eosin (H&E).
10
Relative adipocyte size in H&E sections were estimated by counting the size of adipocytes in 10 random high-
11
powered fields in each sample. The relative cell size was normalized to that of chow diet-fed mice.
12
Immunohistochemical staining was performed using an anti-F4/80 primary antibody (Thermo Fisher Scientific) assessed using Student's t-test or one-way analysis of variance (ANOVA) with Bonferroni's post hoc test. A P value 1 less than 0.05 was considered statistically significant. feeding and were significantly attenuated by gemigliptin treatment (Fig. 2F ).
D r a f t
and MCAD in the livers of WD-fed mice (Fig. 6B) . To examine the effect of gemigliptin on de novo lipogenesis, 1 protein levels of SREBP-1c and FAS in the liver were assessed. Markedly higher levels of SREBP-1c and FAS 2 were found in the livers of WD-fed mice than in chow diet-fed mice (Fig. 6C) . Treatment with gemigliptin resulted 3 in a significant reduction in their increased expression (Fig. 6C ). In addition, mRNA expression of MTTP, a lipid 4 transfer protein required for the assembly and secretion of apolipoprotein B-containing lipoproteins, was also 5 increased in WD-fed mice, but was not affected by gemigliptin treatment (Fig. 6D) . We next examined the effect of 6 gemigliptin on AMPK phosphorylation as AMPK plays an important role in suppressing de novo lipogenesis and 7 increasing fatty acid oxidation (Viollet et al. 2009 ). Gemigliptin treatment significantly increased AMPK 8 phosphorylation in the livers of WD-fed mice (Fig. 6E ).
9
Effect of gemigliptin on hepatic inflammation and fibrosis in WD-fed mice
11
The effect of gemigliptin on WD-induced hepatic inflammation and fibrosis was investigated. H&E staining and
12
Masson's trichrome staining revealed that WD feeding causes ballooning degeneration and fibrosis in livers and 13 these changes were attenuated by gemigliptin treatment (Fig. 7A) . Treatment with gemigliptin also significantly 14 reduced plasma ALT levels in WD-fed mice (Fig. 7B ). In addition, mRNA expression levels of inflammation- These discrepancies may be explained by the differences in the properties of each DPP-4 inhibitor, genetic 9 background and age of mice used, dietary composition, and feeding duration. In the present study, gemigliptin expressed as mean ± SEM. *P < 0.05. NS, not significant. relative to that for chow diet-fed mice. n = 6 per group. All data are expressed as mean ± SEM. *P < 0.05. # P < 0.05 6 compared with WD-fed mice. ×100. n = 6 per group. All data are expressed as mean ± SEM. *P < 0.05. 
